Literature DB >> 8657160

Protein kinase C-theta isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes.

G Baier-Bitterlich1, F Uberall, B Bauer, F Fresser, H Wachter, H Grunicke, G Utermann, A Altman, G Baier.   

Abstract

T-lymphocyte stimulation requires activation of several protein kinases, including the major phorbol ester receptor protein kinase C (PKC), ultimately leading to induction of lymphokines, such as interleukin-2 (IL-2). The revelant PKC isoforms which are involved in the activation cascades of nuclear transcription factors involved in IL-2 production have not yet been clearly defined. We have examined the potential role of two representative PKC isoforms in the induction of the IL-2 gene, i.e., PKC-alpha and PKC-theta, the latter being expressed predominantly in hematopoietic cell lines, particularly T cells. Similar to that of PKC-alpha, PKC-theta overexpression in murine EL4 thymoma cells caused a significant increase in phorbol 12-myristate 13-acetate (PMA)-induced transcriptional activation of full-length IL-2-chloramphenicol acetyltransferase (CAT) and NF-AT-CAT but not of NF-IL2A-CAT or NF-kappaB promoter-CAT reporter gene constructs. Importantly, the critical AP-1 enhancer element was differentially modulated by these two distinct PKC isoenzymes, since only PKC-theta but not PKC-alpha overexpression resulted in an approximately 2.8-fold increase in AP-1-collagenase promoter CAT expression in comparison with the vector control. Deletion of the AP-1 enhancer site in the collagenase promoter rendered it unresponsive to PKC-theta. Expression of a constitutively active mutant PKC-theta A148E (but not PKC-alpha A25E) was sufficient to induce activation of AP-1 transcription factor complex in the absence of PMA stimulation. Conversely, a catalytically inactive PKC-theta K409R (but not PKC-alpha K368R) mutant abrogated endogenous PMA-mediated activation of AP-1 transcriptional complex. Dominant negative mutant Ha-RasS17N completely inhibited the PKC-O A148E-induced signal, PKC-O. Expression of a constitutively active mutant PKC-O A148E (but not PKC-alpha A25E) was sufficient to induce activation of AP-1 transcription factor complex in the absence of PMA stimulation. Conversely, a catalytically inactive PKC-O K409R (but not PKC-alpha K368R) mutant abrogated endogenous PMA-mediated activation of AP-1 transcriptional complex. Dominant negative mutant Ha-enRasS17N completely inhibited in the PKC-O A148E-induced signal, identifying PKC-theta as a specific constituent upstream of or parallel to Ras in the signaling cascade leading to AP transcriptional activation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8657160      PMCID: PMC231171          DOI: 10.1128/MCB.16.4.1842

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  53 in total

1.  Mutagenesis of the pseudosubstrate site of protein kinase C leads to activation.

Authors:  C J Pears; G Kour; C House; B E Kemp; P J Parker
Journal:  Eur J Biochem       Date:  1990-11-26

2.  Nuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cells.

Authors:  A Granelli-Piperno; P Nolan
Journal:  J Immunol       Date:  1991-10-15       Impact factor: 5.422

Review 3.  The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation.

Authors:  P Angel; M Karin
Journal:  Biochim Biophys Acta       Date:  1991-12-10

4.  Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity.

Authors:  W J Boyle; T Smeal; L H Defize; P Angel; J R Woodgett; M Karin; T Hunter
Journal:  Cell       Date:  1991-02-08       Impact factor: 41.582

5.  Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation.

Authors:  N D Perkins; R M Schmid; C S Duckett; K Leung; N R Rice; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

Review 6.  The mechanism of action of cyclosporin A and FK506.

Authors:  S L Schreiber; G R Crabtree
Journal:  Immunol Today       Date:  1992-04

7.  Analysis of the AP-1 sites in the IL-2 promoter.

Authors:  J Jain; V E Valge-Archer; A Rao
Journal:  J Immunol       Date:  1992-02-15       Impact factor: 5.422

8.  Phosphorylation of c-jun mediated by MAP kinases.

Authors:  B J Pulverer; J M Kyriakis; J Avruch; E Nikolakaki; J R Woodgett
Journal:  Nature       Date:  1991-10-17       Impact factor: 49.962

9.  Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73.

Authors:  T Smeal; B Binetruy; D A Mercola; M Birrer; M Karin
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

10.  The AP-1 site at -150 bp, but not the NF-kappa B site, is likely to represent the major target of protein kinase C in the interleukin 2 promoter.

Authors:  J Jain; V E Valge-Archer; A J Sinskey; A Rao
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

View more
  73 in total

Review 1.  Adapters in lymphocyte signaling.

Authors:  Albrecht Leo; Jürgen Wienands; Gottfried Baier; Vaclav Horejsi; Burkhart Schraven
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

Review 2.  PKC-θ is a drug target for prevention of T cell-mediated autoimmunity and allograft rejection.

Authors:  Myung-Ja Kwon; Ruiqing Wang; Jian Ma; Zuoming Sun
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2010-12       Impact factor: 2.895

Review 3.  Emerging and diverse roles of protein kinase C in immune cell signalling.

Authors:  Seng-Lai Tan; Peter J Parker
Journal:  Biochem J       Date:  2003-12-15       Impact factor: 3.857

4.  Novel PKCeta is required to activate replicative functions of the major nonstructural protein NS1 of minute virus of mice.

Authors:  Sylvie Lachmann; Jean Rommeleare; Jürg P F Nüesch
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

5.  The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells.

Authors:  K Belguise; S Milord; F Galtier; G Moquet-Torcy; M Piechaczyk; D Chalbos
Journal:  Oncogene       Date:  2012-01-30       Impact factor: 9.867

6.  Protein kinase Calpha (PKCalpha) acts upstream of PKCtheta to activate IkappaB kinase and NF-kappaB in T lymphocytes.

Authors:  Sergey A Trushin; Kevin N Pennington; Eva M Carmona; Susana Asin; Doris N Savoy; Daniel D Billadeau; Carlos V Paya
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

7.  The small GTP-binding protein Rho potentiates AP-1 transcription in T cells.

Authors:  J H Chang; J C Pratt; S Sawasdikosol; R Kapeller; S J Burakoff
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

8.  A critical role for protein kinase C-theta-mediated T cell survival in cardiac allograft rejection.

Authors:  Santhakumar Manicassamy; Dengping Yin; Zheng Zhang; Luciana L Molinero; Marisa-Luisa Alegre; Zuoming Sun
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

9.  Direct interaction between protein kinase C theta (PKC theta) and 14-3-3 tau in T cells: 14-3-3 overexpression results in inhibition of PKC theta translocation and function.

Authors:  N Meller; Y C Liu; T L Collins; N Bonnefoy-Bérard; G Baier; N Isakov; A Altman
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

10.  Vitamin E inhibits CD95 ligand expression and protects T cells from activation-induced cell death.

Authors:  Min Li-Weber; Markus A Weigand; Marco Giaisi; Dorothee Süss; Monika K Treiber; Sven Baumann; Elena Ritsou; Raoul Breitkreutz; Peter H Krammer
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.